๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 14 Shanghai 7 Guangzhou 4 Suzhou 4 Hangzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing14 Shanghai7 Guangzhou4 Suzhou4 Hangzhou3
All 26 locations
Target enrolment
to

Trials with a site in Beijing

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
NCT07805551CRC, Colorectal Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
220
Beijing
2026-08-18
Not yet open
A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer
NCT07621159Colorectal Cancer Metastatic
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
120
Beijing
2026-07-15
Not yet open
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants
NCT07559240Overweight, Obese
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2026-05-15
Not yet open
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
NCT07417306Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
912
Beijing
2026-03-27
Recruiting
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
NCT07529782Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
15
Beijing, Suzhou, Jinan, Tianjin, Hangzhou
2026-03-17
Recruiting
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT07394114Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
240
Beijing
2026-02-24
Recruiting
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
NCT07274085Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
96
Beijing
2025-11-18
Recruiting
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07193459Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
360
Beijing
2025-08-12
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
NCT07109700Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 2
216
Beijing
2025-04-30
Recruiting
Efficacy and Safety of Semaglutide Injection Vs WEGOVYยฎ in Chinese Obese Patients
NCT07036172Obesity Control
DrugWegovy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
460
Beijing
2025-01-03
Not yet open
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
NCT06601517Healthy Adult Subject, Overweight Subject
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2024-10
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

8 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 14 studies
PhaseStudiesRecruitingShare
Phase 36342.9%
Phase 14228.6%
Phase 1/23221.4%
Phase 2117.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.148
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.